Drug Trial Radar · NCT07348601
A Study of CSTI-500 in Patients With Prader-Willi Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
May 18, 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- ConSynance TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 13 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a proof-of-concept, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CSTI-500 in participants with genetically confirmed Prader-Willi Syndrome (PWS) who are 13 to 50 years of age. Participants will receive increasing doses of CSTI-500, and blood levels will be measured to guide individualized dosing.
Conditions
- Prader-Willi Syndrome
Interventions
CSTI-500Drug
CSTI-500 given orally in an open-label, dose-escalation design with individualized dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: 14 weeks
- Proportion achieving target CSTI-500 steady-state Cmax with PK-guided dose individualizationTime frame: 12 weeks
- Incidence of clinically significant findings in laboratory valuesTime frame: 12 weeks
- Incidence of clinically significant findings in 12-lead electrocardiograms (ECGs)Time frame: 12 weeks
- Incidence of clinically significant findings in vital signsTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.